Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cabaletta Bio Inc (CABA)

Cabaletta Bio Inc (CABA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 90,422
  • Shares Outstanding, K 48,877
  • Annual Sales, $ 0 K
  • Annual Income, $ -67,680 K
  • EBIT $ -115 M
  • EBITDA $ -114 M
  • 60-Month Beta 2.58
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.53

Options Overview Details

View History
  • Implied Volatility 107.10% ( -23.32%)
  • Historical Volatility 79.85%
  • IV Percentile 10%
  • IV Rank 5.90%
  • IV High 861.91% on 08/12/24
  • IV Low 59.81% on 07/31/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 45
  • Volume Avg (30-Day) 468
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 11,122
  • Open Int (30-Day) 14,615

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 5
  • High Estimate -0.63
  • Low Estimate -0.70
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -43.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5900 +11.32%
on 03/04/25
2.9000 -38.97%
on 02/18/25
-0.7600 (-30.04%)
since 02/10/25
3-Month
1.5900 +11.32%
on 03/04/25
3.1500 -43.81%
on 12/12/24
-1.0950 (-38.22%)
since 12/10/24
52-Week
1.5900 +11.32%
on 03/04/25
22.7450 -92.22%
on 03/11/24
-20.7000 (-92.12%)
since 03/08/24

Most Recent Stories

More News
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference

CABA : 1.7700 (-4.32%)
UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

CABA : 1.7700 (-4.32%)
Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

CABA : 1.7700 (-4.32%)
Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

CABA : 1.7700 (-4.32%)
Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

CABA : 1.7700 (-4.32%)
Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

CABA : 1.7700 (-4.32%)
Cabaletta Bio to Participate in Upcoming Investor Conferences in December

CABA : 1.7700 (-4.32%)
2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025

Both penny stocks are a 'strong buy' on Wall Street.

CABA : 1.7700 (-4.32%)
$SPX : 5,614.56 (unch)
NTLA : 9.46 (-8.60%)
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

CABA : 1.7700 (-4.32%)
Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

CABA : 1.7700 (-4.32%)

Business Summary

Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are...

See More

Key Turning Points

3rd Resistance Point 1.9379
2nd Resistance Point 1.8965
1st Resistance Point 1.8332
Last Price 1.7700
1st Support Level 1.7285
2nd Support Level 1.6871
3rd Support Level 1.6238

See More

52-Week High 22.7450
Fibonacci 61.8% 14.6638
Fibonacci 50% 12.1675
Fibonacci 38.2% 9.6712
Last Price 1.7700
52-Week Low 1.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar